Top Page
Genus plc
(LSE:GNS)
Genus plc (GNS) vs. S&P 500 (SPY)
Genus plc Business Overview & Revenue Model
Genus plc Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 668.80M | 689.70M | 593.40M | 574.30M | 551.40M | Gross Profit |
| 178.70M | 239.30M | 226.00M | 232.20M | 211.60M | EBIT |
| 6.40M | 40.50M | 56.60M | 61.50M | 45.40M | EBITDA |
| 73.70M | 87.50M | 79.80M | 82.30M | 68.00M | Net Income Common Stockholders |
| 7.90M | 33.30M | 40.90M | 47.30M | 35.30M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 42.50M | 36.30M | 38.80M | 46.00M | 41.30M | Total Assets |
| 1.03B | 1.01B | 1.02B | 851.00M | 855.40M | Total Debt |
| 291.20M | 232.10M | 223.80M | 151.60M | 143.90M | Net Debt |
| 248.70M | 195.80M | 185.00M | 105.60M | 102.60M | Total Liabilities |
| 485.00M | 440.30M | 445.80M | 354.40M | 360.90M | Stockholders Equity |
| 548.20M | 569.40M | 578.50M | 498.10M | 495.50M |
| Cash Flow | Free Cash Flow | |||
| 5.10M | 15.20M | -7.80M | 38.80M | 35.50M | Operating Cash Flow |
| 29.80M | 50.40M | 34.30M | 67.50M | 60.10M | Investing Cash Flow |
| -19.30M | -30.90M | -67.20M | -46.70M | -25.00M | Financing Cash Flow |
| -2.80M | -18.20M | 21.90M | -14.20M | -23.10M |
Genus plc Technical Analysis
Genus plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | £14.57B | 11.44 | 11.89% | 3.11% | -0.38% | 14.68% | |
77 Outperform | £10.76B | 37.37 | 16.90% | 0.77% | 11.94% | 20.48% | |
72 Outperform | £265.65M | 12.94 | 28.48% | 11.93% | -22.84% | -49.60% | |
66 Neutral | £4.24B | 26.76 | 6.84% | 3.56% | -3.92% | -7.30% | |
62 Neutral | £1.37B | 147.63 | -0.73% | 1.59% | -0.22% | -111.98% | |
53 Neutral | £344.40M | ― | -2.48% | 4.38% | -16.16% | 80.50% | |
52 Neutral | $5.17B | 3.59 | -42.19% | 2.82% | 15.05% | -0.04% |
Genus plc Earnings Call Summary
Genus plc Corporate Events
Genus plc has appointed J.P. Morgan Securities plc as its new Financial Adviser and joint Corporate Broker, alongside Peel Hunt and Panmure Liberum, effective immediately. This strategic move is expected to enhance Genus’s financial advisory capabilities and strengthen its market positioning, potentially impacting its operations and stakeholder relations positively.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score reflects a moderate financial performance with a stable balance sheet but concerns over cash flow and revenue. Positive earnings call insights and recent corporate developments, such as FDA approval and strategic appointments, provide optimism. However, technical indicators and valuation metrics suggest caution, indicating potential challenges in achieving significant upward momentum.
To see Spark’s full report on GB:GNS stock, click here.
Genus plc, listed on the London Stock Exchange under the ticker GNS, announced that as of April 30, 2025, its issued share capital consists of 66,036,776 ordinary shares with voting rights. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score reflects a moderate outlook. Strengths include strategic advancements and a stable balance sheet, but concerns over financial performance and valuation weigh on the score. Technical indicators suggest caution, although recent corporate achievements, like FDA approval, offer a positive outlook for future growth.
To see Spark’s full report on GB:GNS stock, click here.
Genus plc has received FDA approval for its PRRS Resistant Pig gene edit, a significant milestone towards commercializing this innovation in the U.S. food supply chain. This approval is pivotal for the company as it seeks similar regulatory approvals in key export markets like Mexico, Canada, and Japan, and has already received positive determinations from Brazil, Colombia, and the Dominican Republic. The PRRS disease is a major concern in the pork industry, increasing antibiotic use significantly, and Genus’s breakthrough is expected to have a substantial impact on reducing these issues, marking a significant advancement for the industry.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score reflects moderate financial performance with stable balance sheet strengths but concerns over cash flow and revenue. Although the earnings call provided positive strategic insights, technical analysis and valuation metrics indicate caution, suggesting the stock may face challenges in achieving significant upward momentum.
To see Spark’s full report on GB:GNS stock, click here.
Genus plc has announced a change in the voting rights held by Wellington Management Company LLP, which now holds 4.93% of the voting rights, down from a previous position of 5.21%. This adjustment in holdings reflects a disposal of voting rights, indicating a slight shift in the investment stance of Wellington Management, a significant stakeholder in Genus plc. The change could impact the company’s shareholder dynamics and influence future corporate decisions.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score reflects moderate financial performance with stable balance sheet strengths but concerns over cash flow and revenue. Although the earnings call provided positive strategic insights, technical analysis and valuation metrics indicate caution, suggesting the stock may face challenges in achieving significant upward momentum.
To see Spark’s full report on GB:GNS stock, click here.
Genus PLC, a UK-based company, has announced a change in its voting rights structure due to an acquisition or disposal of voting rights by Wellington Management Group LLP, a Boston-based investment management firm. The notification indicates that Wellington Management Group LLP’s voting rights in Genus PLC have decreased from 5.31% to 4.93%. This change in voting rights could impact Genus PLC’s shareholder dynamics and influence within the company, potentially affecting its strategic decisions and stakeholder relations.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc’s overall stock score reflects moderate financial performance with stable balance sheet strengths but concerns over cash flow and revenue. Although the earnings call provided positive strategic insights, technical analysis and valuation metrics indicate caution, suggesting the stock may face challenges in achieving significant upward momentum.
To see Spark’s full report on GB:GNS stock, click here.
Genus plc, a company listed on the London Stock Exchange, has announced the vesting of share awards granted to Jim Low, a member of its Executive Leadership Team. These awards were initially granted to compensate for remuneration forfeited due to his resignation from a previous employer. On March 31, 2025, 10,680 shares vested, and Jim Low sold 4,350 shares to cover tax liabilities, retaining 6,330 shares. This transaction reflects Genus’s commitment to retaining key talent and ensuring competitive compensation packages, which may impact its operational stability and stakeholder confidence.
Genus PLC has announced a change in the voting rights held by BlackRock, Inc., which now holds a total of 5.04% of the company’s voting rights. This change, effective from April 1, 2025, reflects BlackRock’s increased stake in Genus PLC, potentially impacting the company’s shareholder dynamics and market perception.
Genus plc has appointed Andy Russell as the new Chief Financial Officer, effective August 1, 2025, succeeding Alison Henriksen. Russell brings extensive experience from Smith & Nephew plc, where he held senior finance roles. His appointment is expected to support Genus’s strategic priorities and growth opportunities, enhancing its position in the animal genetics industry.
Genus plc has announced that as of 28 February 2025, its issued share capital comprises 66,036,538 ordinary shares with voting rights, and none are held in treasury. This information is crucial for shareholders to calculate their interests or changes in interests under the FCA’s Disclosure Guidance and Transparency Rules.
Genus plc announced the vesting of 44,933 nil-cost options granted over ordinary shares, with CEO Jorgen Kokke selling 19,967 shares to cover tax liabilities and retaining 24,966 shares. This transaction highlights the company’s ongoing management of executive compensation and shareholding strategies, reflecting its commitment to aligning leadership interests with shareholder value.
Genus plc reported a strong financial performance for the first half of the fiscal year, with a 19% increase in adjusted operating profit and a 21% rise in adjusted profit before tax. The company achieved significant cash generation and maintained its interim dividend. Strategic progress was noted in the porcine sector with new customer wins in China and advancements in gene editing technology, while the bovine sector saw improvements through the Value Acceleration Programme. Genus expects continued growth, although geopolitical and currency challenges remain.
Genus plc has announced the retirement of Professor Jason Chin from its Board of Directors, effective May 2025, as he assumes a new role at the Ellison Institute of Technology. Professor Chin, who has served as a Non-Executive Director and Chairman of the Scientific Advisory Board, will continue as a member of the advisory board. The company has begun searching for his successor, highlighting the importance of his contributions to Genus’s scientific advancements.